XNCR - Xencor, Inc.
After hours:
| Previous close | 27.17 |
| Open | 27.24 |
| Bid | 26.97 x 1200 |
| Ask | 27.72 x 800 |
| Day's range | 26.68 - 27.63 |
| 52-week range | 19.35 - 38.20 |
| Volume | |
| Avg. volume | 319,812 |
| Market cap | 1.646B |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.31 |
| Earnings date | 01 Aug 2023 - 07 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 43.00 |
ZacksXencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of -36% and 1.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireXencor Reports First Quarter 2023 Financial Results
PASADENA, Calif., May 08, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a review of recent business and clinical highlights.
Business WireXencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023
PASADENA, Calif., May 01, 2023--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release first quarter 2023 financial results after the market closes on Monday, May 8, 2023.
Business WireXencor Appoints Nancy Valente, M.D., as Chief Development Officer
PASADENA, Calif., April 26, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente, M.D., to Executive Vice President, Chief Development Officer. Dr. Valente has more than 20 years of experience in late-stage biopharmaceutical product development, and she most recently served as a senior vice president at Genentech, a member of
Business WireXencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023
PASADENA, Calif., April 17, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today presented new preclinical data generated from engineered CD28 bispecific antibodies targeting the solid tumor antigens CEACAM5, ENPP3, mesothelin, STEAP1 and Trop-2. For each molecule, in vitro T cell activation was enhanced in combination with a CD3 T cell engager. The data were presente
Business WireXencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023
PASADENA, Calif., March 14, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on novel XmAb® CD28 bispecific antibody programs at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida.
ZacksStrength Seen in Xencor (XNCR): Can Its 5.3% Jump Turn into More Strength?
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Simply Wall St.Xencor, Inc. (NASDAQ:XNCR) Analysts Just Trimmed Their Revenue Forecasts By 13%
The analysts covering Xencor, Inc. ( NASDAQ:XNCR ) delivered a dose of negativity to shareholders today, by making a...
- Simply Wall St.
Xencor Full Year 2022 Earnings: EPS Beats Expectations
Xencor ( NASDAQ:XNCR ) Full Year 2022 Results Key Financial Results Revenue: US$164.6m (down 40% from FY 2021). Net...
ZacksXencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of 75.90% and 8.61%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireXencor Reports Fourth Quarter and Full Year 2022 Financial Results
MONROVIA, Calif., February 23, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a review of recent business and clinical highlights.
ZacksFibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireXencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
MONROVIA, Calif., February 16, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2022 after the market closes on Thursday, February 23, 2023.
- Business Wire
Xencor to Present at the SVB Securities Global Biopharma Conference
MONROVIA, Calif., February 07, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will present at the virtual 2023 SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 3:40 p.m. ET / 12:40 p.m. PT.
Motley FoolWhy Shares of Zencor Rose This Week
Shares of Xencor (NASDAQ: XNCR) rose 12.6% this week as of Thursday afternoon, according to data provided by S&P Global Market Intelligence. The stock closed at $28.83 on Friday and then rose as high as $33.06 on Thursday. Xencor stock was up as high as 14.7% for the week before falling a bit later in the day Thursday.
Business WireXencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates
MONROVIA, Calif., January 09, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.
PR NewswireCaris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates
Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced an expansion of their collaboration to research, develop and commercialize novel XmAb® bispecific and multi-specific antibodies directed agai
Business WireXencor to Present at the 41st Annual J.P. Morgan Healthcare Conference
MONROVIA, Calif., January 04, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023 at 3:45 p.m. PST.
Business WireXencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting
MONROVIA, Calif., December 12, 2022--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced additional clinical data from expansion cohorts in its Phase 1 study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with relapsed or refractory non-Hodgkin lymphomas. Data will be presented by Krish Patel, M.D., Director of the Lymphoma Program at Swedish Cance
ZacksDoes Xencor (XNCR) Have the Potential to Rally 69% as Wall Street Analysts Expect?
The consensus price target hints at a 69.3% upside potential for Xencor (XNCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ZacksXencor (XNCR) Upgraded to Buy: Here's What You Should Know
Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Business WireXencor to Present at Upcoming Investor Conferences
MONROVIA, Calif., November 10, 2022--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate at two upcoming investor conferences:
ZacksCan Xencor (XNCR) Climb 75% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Xencor (XNCR) points to a 74.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Business WireXencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting
MONROVIA, Calif., November 10, 2022--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of data from the first patients in the Phase 2 combination study of vudalimab, a selective PD-1 x CTLA-4 XmAb® bispecific antibody, in patients with metastatic castration-resistant prostate cancer (mCRPC) and data from multiple preclinical-stage XmAb programs
- Zacks
Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of 28.57% and 78.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
